Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Biogen gave the Alzheimer's field something real to argue about this week, and the argument is worth having. At the Alzheimer's Association International Conference, the company presented what BioSpace called an unprecedented drop in tau, the tangled protein that has long been the other half of Alzheimer's biology alongside amyloid. That is genuine validation for the anti tau approach, and it supports Biogen's controversial decision to push diranersen into Phase 3 even though the drug missed its primary endpoint in Phase 2. Lower the toxic protein dramatically, the thinking goes, and the clinical benefit should follow. But the market did not buy it. Biogen shares fell 8% after a fuller look at the mid stage data renewed the obvious question: if you missed your primary endpoint, how much does a biomarker win really tell you, and is there a dosing problem underneath the mixed result? Both things are true at once. The science took a step forward and the clinical case stayed murky. That is Alzheimer's in a sentence.

This lands in the middle of a field that has humbled everyone who has tried it. We have covered the failures all year, Merck killing its Phase 2 program for futility, the parade of amyloid disappointments, the decades of tau programs that went nowhere. Biogen deserves credit for chasing tau when the easy money was on amyloid, and for being transparent enough with the data that the market could push back. But an 8% drop tells you investors have been burned too many times to celebrate a biomarker without a clinical result. For Biogen specifically, this is the boldest bet of its neuroscience pivot, and the one most likely to define whether the new Biogen strategy works.

One eye on tomorrow. Friday is the July 17 deadline for Merck, AbbVie, Lilly, Pfizer and BMS to answer Congress on their China trials. That is the thread we have tracked all week, and we will cover the payoff in tomorrow's edition. The setup could not be more on the nose: today, yet another China origin drug hit a Phase 3 endpoint, this time in melanoma. The science keeps delivering right up to the deadline. 👉 Read Full Analysis

🧠 Neuroscience

Biogen validated the tau approach and got punished anyway. BIIB

At the Alzheimer's Association International Conference, Biogen presented Phase 2 data showing an unprecedented reduction in tau with diranersen, its antisense drug, supporting the company's decision to advance it to Phase 3 despite a missed primary endpoint. BioSpace framed it as hope and validation for the anti tau approach. The market saw it differently. Biogen shares fell 8% after a fuller look at the results renewed questions about the wisdom of a Phase 3 program built on a failed primary endpoint, and raised a dosing question underneath the mixed data. The tension is the whole story. Tau is the protein many researchers believe drives the actual cognitive decline in Alzheimer's, distinct from the amyloid that dominated drug development for two decades. A drug that dramatically lowers it is scientifically important. Whether that translates into patients thinking and remembering better is the question Phase 3 has to answer, and the one the market is not willing to price in yet. This is the defining bet of Biogen's neuroscience pivot.

🔬 Oncology

Celcuity turned a rocky June into its first approval. CELC

The FDA approved Celcuity's Revtorpyk (gedatolisib) for adults with hormone receptor positive, HER2 negative advanced breast cancer without a PIK3CA mutation, after progression on endocrine therapy, according to The Pharma Letter. This is the company's first FDA approval, and it is the same drug we covered in June when it doubled progression free survival but saw its stock drop 25% on questions about the magnitude of benefit. The approval vindicates the program, and the wild type PIK3CA population is a smart place to land, since it is underserved relative to the mutation positive patients other drugs target. Fierce noted Revtorpyk is also in development for prostate cancer and other solid tumors, with multibillion dollar sales potential if those pan out. A reminder that a rough market reaction to a data readout and the ultimate commercial value of a drug are two very different things.

📊 Capital Markets

Earnings season opens with the wind at pharma's back.

Biopharma enters Q2 earnings season riding dealmaking, venture flow, and a clearing of regulatory overhangs, according to BioSpace. Expect management teams to lean into the tailwinds: the record M&A wave, the friendlier FDA posture, and easing policy uncertainty. The IPO market is telling the same story. Biotech public debuts have already eclipsed all of 2025, with Attovia filing this week for an IPO to fund a potential Dupixent challenger and Braveheart Bio heading for Nasdaq to push a Phase 3 cardiovascular drug. After four years in the wilderness, the sector is genuinely healthier, and the Q2 calls will be the first real chance for executives to say so with numbers behind them. The one caveat we keep flagging: the money is pooling at the late stage and commercial end while early stage stays starved. The tailwinds are real, but they are not blowing evenly.

🌍 China

Another China origin drug delivered, one day before the deadline. HUYABIO | BMY

HUYABIO International said HBI-8000 combined with BMS's Opdivo met its primary endpoint in a Phase 3 trial in advanced melanoma, according to The Pharma Letter. HBI-8000 is a drug HUYABIO licensed out of China, making it one more example of a Chinese origin asset producing pivotal data. The timing is almost too perfect. Tomorrow is the July 17 deadline for the five named pharmas to answer Congress on their China trials, and the day before it arrives, the China pipeline delivers another Phase 3 win. This is the tension the whole debate turns on. The political case for restricting China engagement keeps running into the clinical case for continuing it, and the clinical case keeps posting positive data. We will cover the deadline and what the five companies say in tomorrow's edition.

🤖 AI

Chai Discovery raised $400M for AI molecular design.

AI drug discovery firm Chai Discovery raised $400M in a Series C at a $3.8B valuation, according to The Pharma Letter, to expand its molecular design platform across the industry. It continues the steady flow of large AI discovery raises and deals we have tracked, from Isomorphic to Insilico to the Anthropic ecosystem. Notably, this comes the same week Anthropic's own CEO tempered expectations for how fast AI will change biology. The capital is not slowing even as the loudest voices counsel patience, which tells you investors see a long game worth funding now.

📅 Coming Up

👉 Read Full Analysis

The split reaction to Biogen's AAIC data is the story worth understanding, because both sides are right.

The science side. For twenty years, Alzheimer's drug development was dominated by the amyloid hypothesis, the idea that clearing amyloid plaques would slow the disease. The approved amyloid drugs, including Biogen's own Leqembi with Eisai, deliver modest benefit at best. Many researchers have long argued that tau, the protein that forms tangles inside neurons and correlates more tightly with actual cognitive decline, is the more important target. Biogen showing an unprecedented reduction in tau is meaningful evidence that the mechanism is drug addressable, and it strengthens the case for the whole anti tau field, not just diranersen.

The stock side. A biomarker is not a clinical outcome. Diranersen missed its primary endpoint in Phase 2, which is the endpoint that measures whether patients actually did better, not just whether their tau went down. Biogen's decision to advance to Phase 3 anyway rests on a bet that the biomarker will eventually translate, possibly at a different dose. The 8% drop reflects investors who have watched too many Alzheimer's biomarker wins fail to become clinical wins to pay up for another one. The dosing question underneath the data makes it worse, because it hints the Phase 2 design may not have optimized the drug.

The synthesis for anyone holding or watching Biogen. This is the highest variance asset in the company's neuroscience pivot. If the Phase 3 hits, Biogen has a genuinely differentiated Alzheimer's drug in a massive market and the anti tau thesis is vindicated. If it misses, the pivot loses its most important pipeline bet and the skeptics who questioned the Phase 3 decision are proven right. There is not much middle ground. Size the position accordingly, and do not confuse the biomarker validation, which is real, with clinical de risking, which has not happened. The tau field took a step forward this week. Diranersen did not.

💊 Why Celcuity Chose the Wild Type Niche

Celcuity's approval in PIK3CA wild type breast cancer is a smart piece of positioning that is easy to miss. Here is the logic.

In hormone receptor positive, HER2 negative breast cancer, a large share of patients carry PIK3CA mutations, and several drugs, including established PI3K inhibitors, target exactly that population. It is a crowded, well served segment. The wild type patients, those without the mutation, have historically had fewer targeted options after they progress on endocrine therapy, because the obvious biomarker driven drugs were not designed for them.

By landing its approval in the wild type setting, Celcuity avoids a head to head fight in the crowded mutation positive market and instead owns a less contested niche with real unmet need. Gedatolisib hits multiple nodes of the PI3K pathway rather than a single mutation, which is what lets it work in patients without the specific PIK3CA alteration. That mechanistic breadth is the scientific basis for the commercial positioning.

The upside case is bigger than breast cancer. Fierce noted the drug is in development for prostate cancer and other solid tumors. If the pathway biology translates, the wild type breast approval is a beachhead rather than the whole opportunity. For a company landing its first ever approval, establishing the drug in an underserved niche and then expanding into larger indications is exactly the playbook you want to see. The 25% stock drop in June, on worries about the magnitude of the breast cancer benefit, looks in hindsight like the market focusing on the wrong number. The approval and the expansion potential are what matter.

📊 Three Things to Listen For in Q2 Earnings

Q2 earnings season opens with pharma in its best mood in years. Here is what actually matters on the calls.

First, capital allocation intentions. With the M&A wave running hot and four deals already clearing $10B in guaranteed proceeds, the question every large cap will face is what they plan to buy next. Listen for how aggressively management signals continued dealmaking versus buybacks and dividends. The tone will tell you whether the second half M&A pace holds.

Second, China exposure and the political overhang. With the congressional deadline landing tomorrow, analysts will press management on their China strategies. Watch for carefully worded reassurance and for any hint that a company is reconsidering its China licensing pipeline. The gap between what executives say on these calls and what their companies actually do, as AstraZeneca demonstrated this week, is itself the signal.

Third, GLP-1 and the obesity franchise math. For Lilly and Novo, the questions will be about supply, the Medicare Bridge uptake, and the next generation pipeline. Evaluate now projects Lilly's tirzepatide franchise will become the biggest blockbuster ever, topping $70B by 2032. The calls will test whether that trajectory is holding.

The one thing nobody will say out loud: that the early stage funding drought is quietly mortgaging the next decade's pipeline. Every management team benefiting from today's flush late stage market is also watching the seed corn get underfunded, and none of them will make it the headline of a quarter where the numbers look great. But it is the risk that matters most for the 2030s, and the absence of it from the earnings narrative is exactly why it is worth watching.

Biogen moved the tau science forward and lost 8% doing it. Celcuity turned a rough June into its first approval. Earnings season opens with real tailwinds and one quiet risk. And a China origin drug delivered again, one day before the deadline. Tomorrow we cover the payoff. What are you watching? Reply to this email.

👉 Visit The Pro Hub

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →